"Hypotension Probability Indicator" in TAVI/MitraClip for Hypotension Management

January 12, 2025 updated by: Milionis Orestis, Attikon Hospital

Is the Hypotension Probability Indicator with Goal Directed Haemodynamic Treatment Useful in Predicting and Treating Hypotension in Patients Undergoing Transcatheter Aortic Valve Implantation(TAVI) or MitraClip

The study will investigate whether the use of Goal Directed Hemodynamic Therapy implemented with the HPI algorithm using a treatment algorithm will reduce the incidence of hypotension and improve treatment of hypotension.

Study Overview

Detailed Description

The perioperative period is characterized by hemodynamic instability. Intraoperative hypotension (IOH) can be caused by anesthesia drugs, surgical manipulations, hypovolemia or inhibition of the sympathetic nervous system and impairment of baroreflex regulatory mechanisms. In a retrospective analysis performed at the Cleveland Clinic, the risk for acute kidney injury(AKI) and myocardial injury (MI) increased when mean arterial pressure (MAP) was less than 55 mmHg. Further, even short durations of intraoperative hypotension were associated with AKI and MI. Salmasi and coll analyzed whether associations based on relative thresholds were stronger than those based on absolute thresholds regarding blood pressure. They found that there were no clinically important interactions between preoperative blood pressures and the relationship between hypotension and MI or AKI at intraoperative mean arterial blood pressures less than 65 mmHg. Absolute and relative thresholds had comparable ability to discriminate patients with MI or AKI from those without it. The authors concluded that anesthetic management can thus be based on intraoperative pressures without regard to preoperative pressure. In a retrospective cohort study Sun and coll conclude that an increased risk of postoperative stage I AKI occurs when intraoperative MAP was less than 60 mmHg for more than 20 min and less than 55 mmHg for more than 10 min.

Hence it is fundamental for the management of any hemodynamically unstable patient the rapid assessment of the factors that determine the cardiovascular collapse, followed by prompt treatment and, ultimately, reversal of the responsible process. Recently a Hypotension Probability Indicator (HPI) algorithm has been developed from Edwards Lifesciences using continuous invasively-measured arterial waveforms to predict hypotension with high accuracy minutes before blood pressure actually decreases. The HPI algorithm can be integrated with a goal-directed hemodynamic treatment (GDHT) to achieve hemodynamic optimization by increasing global blood flow and prevent organ failure. The HPI index, combined with a hypotension management protocol, has shown efficacy in reducing hypotension during surgical procedures. Its effectiveness has been demonstrated in ICU patients with Covid-19. Studies in cardiac surgery cases have been conducted, with ongoing research in cardiac surgery patients (HYPE2 and HPI Care Trial). Maintaining stable arterial pressure and avoiding intraoperative hypotension are crucial during TAVI or MitraClip procedures, achieved through monitored anesthesia care (MAC) or general anesthesia. Based on recent publications and Pinsky's work, a hypotension management protocol integrating GDHT with the HPI algorithm has been developed for TAVI or MitraClip patients.

Study Type

Interventional

Enrollment (Actual)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Athens, Greece, 12462
        • Attikon Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age >18 years
  • Will be monitored intraoperatively for >1 hour or will receive general anesthesia for >1 hour
  • Will undergo intraoperative monitoring with invasive arterial pressure measurement
  • Mean arterial pressure (MAP) target will be ≥ 65 mmHg intraoperatively
  • Will sign written informed consent preoperatively
  • Will undergo TAVI or Mitral Clip under general anesthesia or monitored anesthesia care (MAC) and sedation
  • American Society of Anesthesiologists (ASA) Physical Status ≤ 4

Exclusion Criteria:

  • Target for MAP different from 65 mmHg
  • Severe hypotension preoperatively MAP <65 mmHg
  • Severe heart failure (e.g., Left Ventricular Ejection Fraction<20%)
  • Patients needing or will need mechanical circulatory support postoperatively (e.g., intra-aortic pump)
  • Urgent surgery
  • Patients with severe pulmonary hypertension (preexisting or detected intraoperatively)
  • Patients with hemodynamic instability requiring extracorporeal circulation support

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: HPI + GDHT treatment
HPI + GDHT using Acumen IQ and Hemosphere monitor with HPI algorithm incorporated following our protocol for hemodynamic treatment (fluids,vasopressors and inotropes).

Hemosphere monitoring and requires the use of a AcumenIQ sensor connected to an arterial line (Edwards Lifesciences Corp., Irvine, CA, USA). The sensor has a splitter which enables the splitting of the arterial blood pressure signal to facilitate a blood pressure signal on both the anesthesia machine monitor (standard care) and the HemoSphere monitor (study).

In the intervention arm we asked the anesthesiologist and anesthesia nurse to use the study treatment flowchart. If the HPI alarm goes off, which entails both a sound and a flickering light, we ask the anesthesiologist to act upon this alarm immediately. Use of the study treatment flowchart ensures that the anesthesiologist has to think about the underlying cause. The HemoSphere with HPI software has a second screen with variables that provide information about the underlying cause of the predicted hypotension.

No Intervention: Control
Conventional treatment with invasive blood pressure monitoring. Administration of fluids and/or vasopressors are guided by standard hemodynamic parameters at the discretion of the attending physician.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
TWA hypotension (measured with Acumen IQ sensor)
Time Frame: Intraoperatively,10 min after induction of anesthesia or commencement of sedation
Time weighted average spent in hypotension (TWA), defined as MAP<65mmHg for ≥1min
Intraoperatively,10 min after induction of anesthesia or commencement of sedation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of hypotension
Time Frame: Intraoperatively,10 min after induction of anesthesia or commencement of sedation
Incidence of hypotension, defined as MAP<65mmHg for ≥1min
Intraoperatively,10 min after induction of anesthesia or commencement of sedation
Time spent in hypotension
Time Frame: Intraoperatively,10 min after induction of anesthesia or commencement of sedation
Time spent in hypotension, in minutes, defined as MAP<65mmHg for ≥1min
Intraoperatively,10 min after induction of anesthesia or commencement of sedation
Treatment choice (drugs/fluids)
Time Frame: Intraoperatively,15 min after induction of anesthesia or commencement of sedation
Medication used to prevent/treat hypotension. A study member is present at the OR to make notes
Intraoperatively,15 min after induction of anesthesia or commencement of sedation
Diagnostic guidance protocol deviations
Time Frame: Intraoperatively,15 min after induction of anesthesia or commencement of sedation
Diagnostic guidance protocol deviations, a study member is present at the OR to make notes
Intraoperatively,15 min after induction of anesthesia or commencement of sedation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tatiana Sidiropoulou, MD,PhD, Attikon Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 10, 2024

Primary Completion (Actual)

December 10, 2024

Study Completion (Actual)

December 10, 2024

Study Registration Dates

First Submitted

March 29, 2024

First Submitted That Met QC Criteria

April 3, 2024

First Posted (Actual)

April 4, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 12, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Attikon Hospital

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

We will share protocol for hemodynamic treatment based on the HPI algorithm as well as raw data

IPD Sharing Time Frame

We will share data after publication

IPD Sharing Access Criteria

individuals who will download/use data must cite location and principal investigator

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypotension During Surgery

Clinical Trials on Acumen IQ sensor with Hemosphere monitor incorporating the HPI algorithm

Subscribe